Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. (Q34778011)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

multiple sclerosis

0 references

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

Anthony O'Hagan

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

7

object named as

Karl Claxton

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Keith R. Abrams

6

object named as

Keith Abrams

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1

object named as

Jim Chilcott

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

3

object named as

Paul Tappenden

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

David H. Miller

8

object named as

David H Miller

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

Chris McCabe

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Nicola J Cooper

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Cost Effectiveness of Multiple Sclerosis Therapies Study Group

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

language of work or name

0 references

publication date

1 March 2003

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

326

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

7388

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

522; discussion 522

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=150460

7 July 2018

Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=150460

7 July 2018

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=150460

7 July 2018

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=150460

7 July 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=150460

7 July 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=150460

7 July 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=150460

7 July 2018

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=150460

7 July 2018

Competing interests in multiple sclerosis research.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=150460

26 October 2018

Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=150460

26 October 2018

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12623909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/12623909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A cost-utility analysis of interferon beta for multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/12623909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/12623909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12623909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BMJ.326.7388.522

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12623909%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34778011&oldid=2054343148"